【product description】
Venetoclax (also translated as: Venetoclax) is the world’s first drug that selectively targets the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers and other cancers, BCL-2 plays a crucial role in preventing cancer cells from dying (apoptosis), and venetoclax can restore it by blocking the BCL-2 protein Apoptotic process. Venetoclax is designed to selectively inhibit the function of BCL-2, restore the cell communication system, allow cancer cells to self-destruct, and achieve the purpose of treating tumors.
【Indications】
- For the treatment of chronic lymphocytic leukemia (CLL) with abnormal chromosome 17p deletion;
- Combined with rituximab for second-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (SLL);
- Combined azacitidine/decitabine/cytarabine first-line treatment of acute myeloid leukemia not suitable for standard induction therapy.
【Dosage】
The dosage is gradually increased every week. The recommended dosage is 20mg/day in the first week, 50mg/day in the second week, 100mg/day in the third week, 200mg/day in the fourth week, until the fifth week and beyond, 400mg/day. until disease progression or unacceptable toxicity. Patients need to take it with food and water at about the same time each day, and the tablet should be swallowed whole without chewing, crushing or breaking before swallowing.
Reviews
There are no reviews yet.